Male breast cancer: Overall survival in a single institution.

Bergmann, Anke; Bello, Marcelo; Bender, Paulo Francisco Mascarenhas; Thuler, Luiz Cláudio Santos

doi:10.1200/jco.2012.30.27_suppl.93

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MBC is usually more advanced at diagnosis than FBC. The OS for MBC patients has ranged between 49 and 87% at 5 years (14,25). A more advanced stage and a higher incidence of lymph node metastases have been linked to a poorer prognosis (26).…”

Section: Discussionmentioning

confidence: 99%

Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment

Zhao

Tang

et al. 2014

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Androgen receptor (AR) plays an important role in male breast cancer (MBC). Additionally, endocrine therapy is the most important treatment in oestrogen receptor (ER)-positive advanced breast cancer. This study was aimed to investigate the role of AR in MBC treatment and prognosis and to analyse the relationship between AR and the effect of tamoxifen treatment in MBC patients. Methods: AR protein levels and other tumour characteristics (e.g. expression of ER (ESR1), PR (PGR), AR, HER2 (ERBB2) and Ki-67 (MKI67)) in breast cancer tissue from 102 MBC patients were determined using immunohistochemical analysis. Additionally, the relationship between AR status and clinicopathological features was analysed using the c 2 -test. Association with survival was initially analysed using the Kaplan-Meier method and the log-rank test, and Cox regression analysis was used to adjust for other prognostic indicators.Results: High expression of AR was not correlated with T-stage, histological grade, HER2 status and the status of other sex hormone receptors, but was associated with lymph node metastases (PZ0.032). AR-positive patients showed significantly shorter 5-year overall survival (OS) rates (PZ0.045) and 5-year disease-free survival (DFS) rates (PZ0.026) than AR-negative patients. By contrast, for patients who received tamoxifen therapy, AR-negative patients showed a higher clinical benefit rate than AR-positive patients (PZ0.025). Additionally, the median TTP and OS were significantly different (PZ0.02 for TTP; PZ0.029 for OS). Conclusions: AR expression correlates strongly with both OS and DFS in patients with MBC. AR-positive patients can predict a poorer clinical outcome than AR-negative patients after adjuvant tamoxifen therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment

Zhao

Tang

et al. 2014

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…In Brazilian study in which 75 male breast cancer patients was included, independent factors associated with increased risk of death were metastasis at diagnosis, older age (≥65 years), higher tumor stage (≥IIb) and positive smoking status (Bergmann et al, 2012). But in study conducted in United States among 2,475 men, age (above 65 years), size and grade of a tumor, involvement of lymph glands and steroid receptors status were identified as independent prognostic factors for breast cancer survival in male (Talluri et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia

Šipetić-Grujičić

Murtezani²,

Z³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The aim of this study was to analyze the demographic and clinical characteristics of male breast cancer patients in Serbia, and furthermore to determine overall survival and predictive factors for prognosis. Materials and Methods: In the period of 1996-2006 histopathological diagnosis of breast cancer was made in 84 males at the Institute for Oncology and Radiology of Serbia. For statistical analyses the Kaplan-Meier method, long-rank test and Cox proportional hazards regression model were used. Results: The mean age at diagnosis with breast cancer was 64.3±10.5 years with a range from 35-84 years. Nearly 80% of the tumors showed ductal histology. About 44% had early tumor stages (I and II) whereas 46.4% and 9.5% of the male exhibitied stages III and IV, respectively. Only 7.1% of male patients were grade one. One-fifth of all patients had tumors measuring ≤2 cm, and 14.3% larger than 5 cm. Lymph node metastasis was recorded in 40.4% patients and 47% relapse. Estrogen and progesterone receptor expression was positive in 66.7% and 58.3%, respectively. Among 14.3% of individuals tumor was HER2 positive. About two-thirds of all male patients had radical mastectomy (66.7%). Adjuvant hormonal (tamoxifene), systematic chemotherapy (CMF or FAC) and adjuvant radiotherapy were given to 59.5%, 35.7% and 29.8% patients respectively. Overall survival rates at five and ten years for male breast cancer were 55.0% and 43.9%, respectively. According to the multivariate Cox regression predictive model, a lower initial disease stage, a lower tumor grade, application of adjuvant hormone therapy and no relapse occurrence were significant independent predictors for good overall survival. Conclusions: Results of the treatment would be better if disease is discovered earlier and therefore health education and screening are an imperative in solving this problem.

show abstract

“…Although AR expression is associated with better outcome in MBC in terms of DFS, it has not been found to improve OS in multivariate analysis [77]. A Brazilian study involving 75 MBC patients that demonstrated distant metastasis at the time of diagnosis, older age ≥65 years, tumor stage ≥IIb and positive smoking status to be negative independent factors associated with an increased mortality risk [78]. Another study conducted in the USA among 2,475 men, aged >65 years identified tumor size & grade as well as involvement of lymph nodes and androgen receptor status as independent prognostic factors for MBC survival [79].…”

Section: Prognosismentioning

confidence: 99%

Overview of male breast cancer

Daniels¹,

Aduse-Poku²,

Gawu³

2023

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Breast cancer (BC) is an epithelial neoplastic disease that usually begins in the ducts or lobules of the breast with the potential to spread to other parts of the body. BC is primarily a disease that affects females but can also occur in men due to the presence of (limited) male breast tissue. Nevertheless, male breast cancer (MBC) should not be seen as just the occurrence of female breast cancer (FBC) in males. Males share common risk factors with postmenopausal women including age, family history, breast cancer gene (BRCA) mutations, and exposure to therapeutic radiation as well as hormonal factors. MBC is uncommon partly because of the masculine endocrine landscape and the relatively limited volume of mammary tissue in males. There is a general lack of awareness of the occurrence of BC in men due to the extremely high incidence of FBC vis- a-vis the rare incidence of MBC. Some men may easily mistake a suspicious breast mass for gynecomastia, a far more common benign occurrence among males. There are currently no international randomized control trials (RCTs) on MBC. Management guidelines in use today are based predominantly on the results of trials conducted among FBC patients. The most effective therapy for MBC is surgery followed by radiotherapy, chemotherapy, and hormonal therapy. Screening for MBC is limited partly due to the absence of large international RCTs demonstrating its usefulness in decreasing MBC-related mortality.

show abstract

Male breast cancer: Overall survival in a single institution.

Cited by 3 publications

References 0 publications

Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment

Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment

Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia

Overview of male breast cancer

Contact Info

Product

Resources

About